Non-Steroidal Anti-Inflammatory Drugs, Lower Oesophageal Sphincter-Relaxing Drugs and Oesophageal Cancer
| Autor: | Andrew Hart, Michael J. C. Rhodes, Ian T. Johnson, Satish Ranka, Jane Skinner, J. M. Gee |
|---|---|
| Rok vydání: | 2006 |
| Předmět: | |
| Zdroj: | Digestion. 74:109-115 |
| ISSN: | 1421-9867 0012-2823 |
| DOI: | 10.1159/000097947 |
| Popis: | Background and Aims: The incidence of oesophageal cancer has doubled in the last three decades. Non-steroidal anti-inflammatory drugs (NSAIDs) may be protective, whilst bronchodilators and calcium channel blockers that relax the lower oesophageal sphincter (LOS) may increase gastro-oesophageal reflux and the risk of oesophageal adenocarcinoma. We conducted a case-control study to examine the association between the use of NSAIDs and drugs which relax the LOS and the risk of oesophageal cancer. Methods: In Norfolk, 411 patients with a primary neoplasm of the oesophagus or cardia were matched with 1,644 controls with non-melanotic skin lesions. Data on the use of NSAIDs, bronchodilators and calcium channel blockers was collected. Results: Intake of NSAIDs was less in cases of oesophageal cancer as compared to the control group. The odds ratios (OR) and 95% confidence intervals (CI) for different NSAIDs were as follows: aspirin 0.35 (0.24–0.51); other NSAIDs 0.25 (0.16–0.40), and Cox-2 inhibitors 0.46 (0.20–0.94). LOS-relaxing drugs were consumed more frequently in cases of oesophageal cancer as compared to the controls. The OR for LOS-relaxing drugs was: inhaled bronchodilators 3.2 (95% CI 2.2–4.7); theophylline 1.9 (95% CI 1.3–5.1), and calcium channel blockers 2.4 (95% CI 1.2–5.0). Conclusion: Within the limitations of a case-control study using patients with non-melanotic skin lesions as controls, our results are consistent with the hypothesis that oesophageal cancer has a negative association with NSAID use, and a positive association with drugs that relax the LOS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|